×

Business Strategy Business Competition

  • Price of innovation in pharma: Pro

    Kevin Sharer, Harvard Business School, discusses competition in the pharmaceutical industry and balancing drug prices and profits.

  • US economy caught in DC gridlock: Michael Porter

    The amount of legislation being passed now is virtually at an all-time low, says Michael Porter, Harvard Business School sharing his thoughts on what's impeding economic growth in the U.S.

  • Michael Porter: US 'tangled up' in tax structure

    The real barrier to our prosperity is Washington, says Michael Porter, Harvard Business School, discussing how U.S. corporate tax policy is limiting global competitiveness for the nation's companies.

  • A worker assembles a box spring at the McRoskey Mattress facility in San Francisco.

    We are stalled in America and small business is struggling, says Michael Porter, Harvard Business School, with Jan Rivkin, HBS business professor, discussing the results of Harvard's fifth annual survey which shows the U.S. lagging in competitiveness.

  • Ocado would benefit from new competitor Amazon Fresh taking on some of its rivals, an analyst told CNBC.

  • Donuts enter breakfast battle

    CNBC's Susan Li reports there's a new competitor in the war to win consumers for America's morning meal - Federal Donuts, and it has taken the market by storm. Restaurateur Michael Solomonov explains.

  • Power of endorsements: Pro

    Suan Anderson, FBR Capital Markets, shares her outlook on Under Armour as sneaker wars heat up in Asia.

  • Sneaker wars rage on in Asia

    CNBC's Sara Eisen talks to Kevin Plank, Under Armour CEO and the NBA's Stephen Curry about competing against established brands in Asia.

  • Valdis Dombrovskis

    The U.K. cannot "cherry pick" the parts of the single market it wants to keep when it quits the European Union, Valdis Dombrovskis told CNBC.

  • What should an EpiPen cost?

    Scott Gottlieb, AEI resident fellow, and Sam Waksal, Kadmon Corporation, discuss how competition impacts drug pricing and whether the FDA is working fast enough to streamline its approval process.

  • Beyond Wal-Mart's numbers

    CNBC's Landon Dowdy takes a look at three key things Wall Street will be watching when Wal-Mart reports quarterly results.

  • ACIA CEO: Duel technologies fuels growth

    Raj Shanmugaraj, Acacia Communications CEO breaks down the company's blowout quarter and shares his outlook on growth and explains how incorporating two technologies keeps the company ahead of the competition.

  • We are not interested in Monster: Adecco CEO

    Alain Dehaze, CEO of Adecco, comments on the merger between rivals Randstad and Monster and says his company is not considering a bid for Monster.

  • Wal-Mart's $3B bet

    CNBC contributor Jan Kniffen and Ken Perkins, Morningstar Equity Analyst, discuss their views on Wal-Mart's $3 billion bet.

  • Jersey Mike's sub success

    Hoyt Jones, Jersey Mike's president, discusses how a single storefront became one of the nation's fastest-growing fast casual dining chains.

  • T-Mobile CEO: I love to see VZ & S fighting

    T-Mobile USA President and CEO John Legere reacts to the former Verizon advertisement actor now with Sprint, and competition in the space.

  • Ariad confident on cancer drug data

    Ariad Pharmaceuticals President and CEO Paris Panayiotopoulos, discusses patient response to cancer treatment Brigatinib.

  • Must Read: Keep America strong

    The "Worldwide Exchange" crew discusses some of the morning's top attention-grabbing headlines, including a story in the Washington Post titled "America is still great - but needs to stay strong," and a Financial Times piece titled, "Put tired James Bond out of his misery."

  • Does Android have a monopoly in Europe?

    Eric Schmidt, executive chairman of Alphabet, says he disagrees with European regulators over competition issues.

  • A man operates a Apple iPhone at a mobile phone store in in Mumbai, India.

    Will Power, Robert W. Baird analyst, weighs in on Apple's decline and what's ahead for the tech giant.